ArticleBioengineering (Basel, Switzerland)2023
Explainable Vision Transformer with Self-Supervised Learning to Predict Alzheimer's Disease Progression Using 18F-FDG PET.
Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Hybrid CNN-Transformer Framework for Molecular Imaging-based Early Alzheimer's Disease Detection.Molecular imaging and biology · 2026Article
- Use of explainable AI (xAI) in dementia detection and prognosis: a scoping review.BMC medical informatics and decision making · 2026Article
- Enhancing Alzheimer's disease classification with a transformer-based model using self-supervised learning.Scientific reports · 2026Article
- Topology-aware hybrid graph-transformer network for Alzheimer's disease diagnosis from structural magnetic resonance imaging.Frontiers in computational neuroscience · 2026Article
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea) · 2026Article
- Vision and convolutional transformers for Alzheimer's disease diagnosis: a systematic review of architectures, multimodal fusion and critical gaps.Brain informatics · 2025Review
- Multimodal Self-Supervised Learning for Early Alzheimer's: Cross-Modal MRI-PET, Longitudinal Signals, and Site Invariance.Diagnostics (Basel, Switzerland) · 2025Article
- Early detection of Alzheimer's disease progression stages using hybrid of CNN and transformer encoder models.Scientific reports · 2025Article
- Harnessing artificial intelligence for brain disease: advances in diagnosis, drug discovery, and closed-loop therapeutics.Frontiers in neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. Early and accurate prediction of AD progression is crucial for early intervention and personalized treatment planning. Although AD does not yet have a reliable therapy, several medications help slow down the disease's progression. However, more study is still needed to develop reliable methods for detecting AD and its phases. In the recent past, biomarkers associated with AD have been identified using neuroimaging methods. To uncover biomarkers, deep learning techniques have quickly emerged as a crucial methodology. A functional molecular imaging technique known as fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has been shown to be effective in assisting researchers in understanding the morphological and neurological alterations to the brain associated with AD. Convolutional neural networks (CNNs) have also long dominated the field of AD progression and have been the subject of substantial research, while more recent approaches like vision transformers (ViT) have not yet been fully investigated. In this paper, we present a self-supervised learning (SSL) method to automatically acquire meaningful AD characteristics using the ViT architecture by pretraining the feature extractor using the self-distillation with no labels (DINO) and extreme learning machine (ELM) as classifier models. In this work, we examined a technique for predicting mild cognitive impairment (MCI) to AD utilizing an SSL model which learns powerful representations from unlabeled 18F-FDG PET images, thus reducing the need for large-labeled datasets. In comparison to several earlier approaches, our strategy showed state-of-the-art classification performance in terms of accuracy (92.31%), specificity (90.21%), and sensitivity (95.50%). Then, to make the suggested model easier to understand, we highlighted the brain regions that significantly influence the prediction of MCI development. Our methods offer a precise and efficient strategy for predicting the transition from MCI to AD. In conclusion, this research presents a novel Explainable SSL-ViT model that can accurately predict AD progress based on 18F-FDG PET scans. SSL, attention, and ELM mechanisms are integrated into the model to make it more predictive and interpretable. Future research will enable the development of viable treatments for neurodegenerative disorders by combining brain areas contributing to projection with observed anatomical traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.